The Neuroscience of Parkinson's Disease
Herausgeber: R Martin, Colin; Preedy, Victor R
The Neuroscience of Parkinson's Disease
Herausgeber: R Martin, Colin; Preedy, Victor R
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The Neuroscience of Parkinson's Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson's disease-from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.…mehr
- Huntington's Disease163,99 €
- Jahangir MoiniGlobal Emergency of Mental Disorders213,99 €
- Jahangir MoiniFoundations of the Mind, Brain, and Behavioral Relationships265,99 €
- P Hemachandra ReddyCovid-19 in Alzheimer's Disease and Dementia163,99 €
- Adolescent Psychosis160,99 €
- Handbook of Digital Technologies in Movement Disorders160,99 €
- Alfred DavidThe Secret Life of the Brain22,99 €
-
-
-
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
- Produktdetails
- Verlag: Elsevier Science
- Seitenzahl: 1612
- Erscheinungstermin: 23. September 2020
- Englisch
- Gewicht: 3830g
- ISBN-13: 9780128159583
- ISBN-10: 0128159588
- Artikelnr.: 58855283
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: Elsevier Science
- Seitenzahl: 1612
- Erscheinungstermin: 23. September 2020
- Englisch
- Gewicht: 3830g
- ISBN-13: 9780128159583
- ISBN-10: 0128159588
- Artikelnr.: 58855283
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Parkinson's Disease - from early 19th century and afterwards - an
overview2. Living with Parkinson's disease - from financial to emotional3.
The epidemiology of Parkinson's disease - an overview4. Clinical Features
of Parkinson's disease - an overview5. The natural history of Parkinson's
disease - an overview6. The prognosis of Parkinson's disease - an
overview7. The neurobiology of Parkinson's disease - an overview8. The
pathophysiology of Parkinson's disease - an overview9. Molecular and
cellular mechanisms associated with Parkinson's disease - synuclein,
amyloid protein, oligomers and beyond10. Quality of life in Parkinson's
disease11. Gait in untreated Parkinson's disease12. Levodopa-induced
dyskinesias13. Tremor in Parkinson's disease14. The impact of Parkinson's
disease on the family and careers
Section 2 Biomarkers and Diagnosis15. Tissue biopsies as biomarkers in
Parkinson's disease16. Spinal fluid for biomarker discovery in Parkinson's
disease17. Clinical biomarkers in prodromal Parkinson's disease18. The
diagnosis of Parkinson's disease19. Proteomics in Parkinson's disease20.
MicroRNAs as biomarkers in Parkinson's diseases21. Phenotyping in
Parkinson's disease22. Diagnosis of speech disorders in Parkinson's
disease23. Identifying dementia in Parkinson's disease24. Diagnosis of
sleep disturbances in Parkinson's disease25. Diagnosis of Parkinson's
disease using magnetic resonance imaging26. Use of ultrasound as a
diagnostic tool in Parkinson's disease27. Use of single-photon emission
computerized tomography (SPECT) as a diagnostic tool in Parkinson's
disease28. Use of positron emission tomography (PET) as a diagnostic tool
in Parkinson's disease
Section 3 Pharmacological Treatments for Parkinson's Disease29. Dopamine
Agonists and Parkinson's disease - an overview30. Management with Levodopa
in Parkinson's disease31. Management with ripinirole in Parkinson's
disease32. Management with pramipexole in Parkinson's disease33. Management
with rotigotine in Parkinson's disease34. Management with apomorphine in
Parkinson's disease35. Management with MAO-B Inhibitors in Parkinson's
disease36. Management with COMT inhibitors in Parkinson's disease37.
Management with anticholinergics in Parkinson's disease38. Management with
amantadine in Parkinson's disease
Section 4 Novel and Non-Pharmacological Therapies For Parkinson's Disease
39. Treatment with chelator in Parkinson's disease40. Treatment with deep
brain stimulation in Parkinson's disease41. Olive leaf extract usage as an
antioxidant and applications to Parkinson's disease42. Treatment with
Vitamin D for Parkinson's disease43. Chemogenetics and applications for
Parkinson's disease44. Flavonoids and naringin usage in Parkinson's
disease45. Stem cells and applications to Parkinson's disease46. Treatment
with cannabis for Parkinson's disease47. Treating sleep problems in
Parkinson's disease48. Perioperative treatments of Parkinson's disease49.
Exercise and Parkinson's disease50. Molecular aspects: CB2 receptors and
neuroprotection in Parkinson's disease
Parkinson's Disease - from early 19th century and afterwards - an
overview2. Living with Parkinson's disease - from financial to emotional3.
The epidemiology of Parkinson's disease - an overview4. Clinical Features
of Parkinson's disease - an overview5. The natural history of Parkinson's
disease - an overview6. The prognosis of Parkinson's disease - an
overview7. The neurobiology of Parkinson's disease - an overview8. The
pathophysiology of Parkinson's disease - an overview9. Molecular and
cellular mechanisms associated with Parkinson's disease - synuclein,
amyloid protein, oligomers and beyond10. Quality of life in Parkinson's
disease11. Gait in untreated Parkinson's disease12. Levodopa-induced
dyskinesias13. Tremor in Parkinson's disease14. The impact of Parkinson's
disease on the family and careers
Section 2 Biomarkers and Diagnosis15. Tissue biopsies as biomarkers in
Parkinson's disease16. Spinal fluid for biomarker discovery in Parkinson's
disease17. Clinical biomarkers in prodromal Parkinson's disease18. The
diagnosis of Parkinson's disease19. Proteomics in Parkinson's disease20.
MicroRNAs as biomarkers in Parkinson's diseases21. Phenotyping in
Parkinson's disease22. Diagnosis of speech disorders in Parkinson's
disease23. Identifying dementia in Parkinson's disease24. Diagnosis of
sleep disturbances in Parkinson's disease25. Diagnosis of Parkinson's
disease using magnetic resonance imaging26. Use of ultrasound as a
diagnostic tool in Parkinson's disease27. Use of single-photon emission
computerized tomography (SPECT) as a diagnostic tool in Parkinson's
disease28. Use of positron emission tomography (PET) as a diagnostic tool
in Parkinson's disease
Section 3 Pharmacological Treatments for Parkinson's Disease29. Dopamine
Agonists and Parkinson's disease - an overview30. Management with Levodopa
in Parkinson's disease31. Management with ripinirole in Parkinson's
disease32. Management with pramipexole in Parkinson's disease33. Management
with rotigotine in Parkinson's disease34. Management with apomorphine in
Parkinson's disease35. Management with MAO-B Inhibitors in Parkinson's
disease36. Management with COMT inhibitors in Parkinson's disease37.
Management with anticholinergics in Parkinson's disease38. Management with
amantadine in Parkinson's disease
Section 4 Novel and Non-Pharmacological Therapies For Parkinson's Disease
39. Treatment with chelator in Parkinson's disease40. Treatment with deep
brain stimulation in Parkinson's disease41. Olive leaf extract usage as an
antioxidant and applications to Parkinson's disease42. Treatment with
Vitamin D for Parkinson's disease43. Chemogenetics and applications for
Parkinson's disease44. Flavonoids and naringin usage in Parkinson's
disease45. Stem cells and applications to Parkinson's disease46. Treatment
with cannabis for Parkinson's disease47. Treating sleep problems in
Parkinson's disease48. Perioperative treatments of Parkinson's disease49.
Exercise and Parkinson's disease50. Molecular aspects: CB2 receptors and
neuroprotection in Parkinson's disease